Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills won’t wait for prescriptions—and the industry needs to prepare for that reality.

MedicinManAI Feature

Let us set aside the clinical ideal for a moment. No amount of regulatory advisory or media noise from the medical establishment will change the fundamental reality of Indian healthcare.

India is not a clinic-first country. It is a pharmacy-first country.

With over one million retail pharmacies serving as the de facto primary healthcare system, India’s drug market functions as a parallel universe of affordable, accessible healthcare. For the average citizen, the pharmacy is cheaper, faster, and more approachable than a doctor’s clinic. It is the first point of access for everything—from antibiotics for a fever to AYUSH remedies for joint pain to “general products” for daily wellness.

This is a highly lucrative business for retail pharmacies. And it is virtually impossible to regulate one million outlets across 28 states and 8 union territories.

Now, add to this the existence of thousands of small drug companies that sell trade generics directly to retail pharmacies at mind-boggling margins. These are not the Sun Pharmas and Dr. Reddy’s of the world. These are regional, often unlisted manufacturers who bypass the standard distribution chain, offering pharmacists 70–80% margins on certain products.

Into this ecosystem, oral GLP-1 weight-loss pills are about to arrive.

The question is not whether they will be accessed responsibly, with a prescription and clinical supervision. The question is: How quickly will they bypass the clinic and reach the pharmacy counter—and who will profit?

The Logistical Liberation

For years, the injectable GLP-1 market was self-regulating. The need for cold-chain infrastructure and the psychological hurdle of self-administration kept these drugs in a relatively narrow clinical channel. A patient could not casually buy a refrigerated injectable pen from a corner pharmacy.

Oral, non-peptide GLP-1 molecules change everything.

These small molecules—pioneered by Eli Lilly (Orforglipron) and a cohort of Chinese biotech innovators including Hengrui (HRS-7535), Huadong (Conveglipron), Innovent Biologics, and Ascletis (ASC30) —do not require refrigeration. They are small, shelf-stable pills. They look like any other tablet on the pharmacy shelf.

The weight-loss efficacy of these oral options ranges from 10–16%, according to industry experts quoted in The Economic Times (April 2026). For the needle-phobic population—and for the pharmacy-first patient—this is more than sufficient.

Dr. Rajiv Kovil, a Mumbai-based diabetologist, told The Economic Times: “Unlike injections, these tablets don’t need cold storage and are more convenient which matters a lot in India.”

Convenience is the mother of consumerisation.

The Oral Players: Who Is Coming to India?

Indian companies are expected to partner with Chinese firms for clinical development and commercial rights, similar to existing partnerships in the injectable space—such as Lupin’s alliance with Gan & Lee Pharmaceuticals for a twice-a-month injectable GLP-1.

But the real action will not be at the branded generic level. The real action will be at the trade generic level—the thousands of small manufacturers who will reverse-engineer, reformulate, or simply copy these molecules once regulatory pathways become clear.

The Unspoken Reality: India’s Consumerised Drug Market

Let us name what the industry whispers but rarely prints.

India’s retail pharmacy network is not just a distribution channel. It is a parallel healthcare system:

The DCGI can issue all the advisories it wants against surrogate advertising and prescription-free sales. But the ground reality is that a million pharmacies cannot be policed. Thousands of small drug companies—many operating just within (or just outside) the legal framework—will see oral GLP-1s as the next gold rush.

And they will be right.

Consider the precedent:

• Antibiotics are sold over the counter for viral fevers, despite knowing it drives antimicrobial resistance.
• Steroids are freely available for “weight gain” and “skin lightening.”
• Painkillers are consumed like candy for chronic back pain.
• Anti-diabetic drugs like metformin are often started without a formal diagnosis.

Why would oral GLP-1s be any different?

They will not be.

The Quality Paradox

At this point, a thoughtful reader might object: But what about quality? Surely patients deserve medicines that are safe and effective.

This is precisely the argument that Anup Soans, editor of MedicinMan.net and a longtime observer of Indian pharmaceutical distribution, has been making for nearly a decade. In his 2017 Wire Science article, he wrote:

“The issue in India is not about expensive brand name drugs versus cheaper generics, as in the West, but one of quality drugs versus suspect quality drugs.

Branded generics are also generics with a brand name, plus the quality assurance from well-known companies like Cipla, Sun or Dr Reddy’s.

Doctors have come to trust these companies and their brands over time.”

Soans introduced the now-famous phrase that the term ‘branded generic’ is an Indian creation, “an oxymoron and jugaad” for Indian pharma to distinguish its generics from others. His core argument, restated in a February 2026 MedicinMan article, is that the generic drug debate in India is routinely misframed around price when the real issue is quality—specifically, whether drugs meet defined standards of bioequivalence and ongoing manufacturing compliance.

He writes:

“Generic medicines do not derive legitimacy from being cheaper.

They derive it from meeting the same scientific and regulatory standards as branded drugs—beginning with bioequivalence in human blood and continuing with quality compliance in manufacture.”

In the Indian context, however, this creates a paradox. In the absence of a strong, trusted regulator (like the USFDA), doctors and patients fall back on brand reputation as a proxy for quality. As Soans notes in his LinkedIn post summarizing the same argument:

“In the absence of an international standard drug regulatory mechanism like the USFDA, Indian doctors have to rely on the reputation of companies like Cipla, Sun and hundreds of others who have demonstrated their commitment to quality over time and become trusted names in the eyes of doctors and patients.”

Now apply this to oral GLP-1s.

The trade generic players entering this market will not have the quality reputation of a Sun Pharma or a Dr. Reddy’s. They will be unknown entities, manufacturing in small, low-overhead facilities, with minimal regulatory compliance. And yet, because the retail pharmacy channel operates on margin and availability—not quality signaling—these products will still sell.

This is the quality paradox of the Indian market: the very mechanism doctors use to ensure quality (brand trust) is absent from the trade generic channel. But the channel does not care. The pharmacy bhaiya does not check bioequivalence data. He checks his margin.

A Counterpoint: The Vested Interest Argument

Not everyone agrees with Soans’ framing. In a 2018 article in Economic and Political Weekly (EPW), researcher Manu Kanchan argued that the pharmaceutical industry has vested interests in making arguments against generic drugs—including the quality argument.

Kanchan writes:

“The perception that unbranded generics are of suspect quality… has been built by the pharmaceutical companies themselves to their advantage. The perception acts as an entry barrier for unbranded drugs and this has become possible due to the absence of a strong drug regulatory authority in India.”

He points out that studies have found unbranded generics from government supply chains (like Jan Aushadhi) to be as good in quality as branded counterparts. Conversely, branded drugs from “reputed” companies have repeatedly failed quality tests.

This counterpoint is valuable because it reminds us that quality is not the exclusive domain of large branded players. A well-regulated generic—whether branded or unbranded—can be perfectly safe and effective.

However, Kanchan’s argument assumes a functioning regulator that enforces quality uniformly. In India’s current environment, that assumption is fragile. And for oral GLP-1s entering through the trade generic channel, the likelihood of rigorous quality oversight is low.

The strategic implication is not to dismiss quality concerns. It is to recognise that in the absence of regulatory trust, the market will default to the next best thing: brand reputation or, failing that, price and margin.

The “Vitaminization” of Metabolic Health

The earlier article in this series introduced the concept of “vitaminization” —the transformation of a prescription drug into a consumer wellness product. The difference is that most vitamins are harmless in overdose. GLP-1s are not.

When oral GLP-1s become available through the retail pharmacy channel—with or without a prescription—the following will happen:

But here is the strategic paradox: None of this will slow down adoption. If anything, it will accelerate it.

The same “pharmacy bhaiya” who recommends a painkiller for a headache will recommend an oral GLP-1 for “that stubborn belly fat.” The same small manufacturer who produces trade generic antibiotics will produce trade generic orforglipron.

The medics will cry foul. The regulator will issue circulars. The media will run exposés.

And the pharmacies will keep selling.

The Strategic Implications for Indian Pharma (The Real Ones)

Given this reality, what should serious pharmaceutical companies do?

Drawing on Soans’ framework, the first step is to recognise that quality is not just a regulatory requirement—it is a potential differentiator. But in the trade generic channel, quality does not sell. Margin sells.

So how does a responsible company compete?

Option 1: Ignore the parallel market and focus on the clinical channel.

This is the “safe” strategy. Build relationships with endocrinologists. Launch a branded generic at a premium price. Invest in patient education programs. Comply with every regulation.

Outcome: You will capture 10–15% of the addressable market. The other 85–90% will go to the trade generic players who have no such compunctions.

Option 2: Complain about the regulator and the “unethical” players.

This is the “frustrated incumbent” strategy. Write letters. Seek enforcement. Lobby for stricter controls.

Outcome: You will waste three years and achieve nothing. The parallel market will grow regardless.

Option 3: Accept the reality and compete where the volume is.

This is the “realist” strategy. Recognise that India’s consumerised drug market is not going to change. Instead of ceding the space to fly-by-night operators, build a legitimate but accessible oral GLP-1 offering that:

• Prices aggressively to undercut the trade generic incentive (if the legal product is cheap enough, the illegal product has no margin advantage)
• Simplifies the packaging and information for pharmacy-led dispensing
• Creates a basic adherence and safety protocol that pharmacies can actually follow (e.g., “start with half a tablet for week one” rather than a 30-page patient insert)
• Partners with pharmacy chains (not just clinics) as distribution partners

Outcome: You capture volume, build brand recognition at the retail level, and potentially set a safety floor where none exists today.

The Trade Generic Threat And Opportunity

The thousands of small drug companies that sell trade generics directly to retail pharmacies are not going to disappear. They operate on a simple model:

For a pharmacist, recommending a trade generic oral GLP-1 is not unethical—it is rational business. The customer wants affordable weight loss. The pharmacist wants margin. The small manufacturer wants volume.

The only party missing from this transaction is the doctor. And in India’s pharmacy-first healthcare system, that is not a bug. It is a feature.

The Verdict

The battle is shifting from injectable to oral. But that is not the real story.

The real story is that oral GLP-1s will bypass the clinic entirely for a significant portion of the market—and no amount of medical outrage or regulatory circulars will stop it.

The question for serious Indian pharmaceutical companies is not “How do we prevent this?” That battle is already lost.

The question is: Do you want to be part of the responsible, regulated, accessible channel—or will you cede the entire volume market to trade generic players who have no interest in patient safety?

The companies that succeed will be those who:

1. Price realistically for the pharmacy-first consumer, not the specialist-prescribed premium segment.
2. Distribute through pharmacy chains as legitimate partners, not adversaries.
3. Simplify safety into protocols that a pharmacy can actually implement.
4. Accept the consumerisation of metabolic health as inevitable and work within it, rather than against it.

As Soans reminds us, the core issue in Indian pharmaceuticals has never been price alone—it is quality, and the trust that quality requires. But in a market where the regulator is weak and the retail channel is king, trust is a scarce commodity. The companies that build that trust—through consistent quality, accessible pricing, and pharmacy-friendly formats—will not merely sell oral GLP-1s. They will define the responsible future of metabolic healthcare in India.

The alternative is to watch from the sidelines as the trade generic players build a billion-dollar oral GLP-1 market—one pharmacy counter at a time.

— MedicinMan Strategy Desk

Appendix: Primary Sources

Primary Source (Oral GLP-1 Market)

Bhattacharyya, R. (April 2026). Obesity Drug Mkt to Gain as Indians Pop the Pill and Chinese Bring More. The Economic Times (Mumbai edition).

Secondary Sources

Soans, A. (2017, May 3). Quality, Not Price, is the Key Issue When Prescribing Generic Drugs in India. The Wire Science.

• Introduces the concept of ‘branded generic’ as an Indian oxymoron and jugaad
• Argues that in the absence of a strong regulator, doctors rely on company reputation
• Notes that India’s 800,000+ retailers have thrived on high-margin trade generics
• Discusses the power of AIOCD and the difficulty of enforcing generic-only prescriptions

Soans, A. (2026, February 1). Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point. MedicinMan.

• Restates the core argument that bioequivalence is the foundational pillar of generic drug quality
• Argues that the debate is misframed around price when it should be about regulatory standards
• Emphasises that confidence in medicines flows from confidence in regulation
• Calls for transparency in post-marketing surveillance and bioequivalence data

Soans, A. (2025, May 3). Branded generics: Quality and trust over cheaper drugs. LinkedIn post (summarising the 2017 Wire Science article).

• Condensed version of the quality-versus-price argument
• Highlights the role of nearly one million medical representatives in building brand trust

Kanchan, M. (2018, August 30). The Pharmaceutical Industry Has Vested Interests in Making Arguments against Generic Drugs. Economic and Political Weekly (EPW) Engage.

• Counterpoint to Soans: argues that the quality argument serves industry vested interests
• Presents data on inter-brand price differences (up to 700%+)
• Notes that unbranded generics from Jan Aushadhi and state supply chains have been found to be of equivalent quality
• Points out that branded drugs from “reputed” companies have repeatedly failed quality tests
• Calls for strengthening the drug regulator and making UCPMP mandatory

Secondary Sources (Retail Pharmacy & Trade Generic Context)

AIOCD (All India Organisation of Chemists & Druggists). Retail Pharmacy Census 2025. Estimates over 1 million retail pharmacy outlets in India.

IQVIA (2024). Trade Generics in India: The Unseen Market. Estimates trade generics constitute 25–30% of the Indian pharmaceutical market by volume, with margins 3–4x higher than branded generics.

Methodology Note

The characterisation of India as a “consumerised drug market,” the “pharmacy-first” framing, the trade generic business model analysis, and the three strategic options for Indian pharma are original to this MedicinMan article. The integration of Anup Soans’ quality-versus-price framework and Manu Kanchan’s counterpoint provides a nuanced, source-backed foundation for the article’s central tension: quality as a differentiator versus the retail channel’s preference for margin and availability.

MedicinMan is an Indian Pharma and Healthcare centred publication portal. This article is intended for industry professionals and does not constitute investment or regulatory advice.

All Images are AI Generated for Illustration Only. E&OE